Arrevus Revenue and Competitors
Estimated Revenue & Valuation
- Arrevus's estimated annual revenue is currently $930k per year.
- Arrevus's estimated revenue per employee is $155,000
Employee Data
- Arrevus has 6 Employees.
- Arrevus grew their employee count by -45% last year.
Arrevus's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder and CEO | Reveal Email/Phone |
2 | Facilities and Administration Manager | Reveal Email/Phone |
3 | Scientific Advisor | Reveal Email/Phone |
4 | Clinical Development Advisor | Reveal Email/Phone |
Arrevus Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is Arrevus?
Arrevus is a clinical-stage biotechnology company developing novel therapies for orphan diseases. Our mission is to develop therapeutics for unmet medical needs in areas with high treatment failure rates, few therapeutic options, and serious outcomes. Arrevus is advancing ARV-1801, a Phase III clinical program targeting cystic fibrosis pulmonary exacerbations. Arrevus is also advancing preclinical programs to address unmet needs in oncology and antimicrobial resistance.
keywords:N/AN/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-45%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 6 | 0% | N/A |
#2 | $0.6M | 6 | 0% | N/A |
#3 | $0.4M | 6 | 0% | N/A |
#4 | $0.6M | 6 | 0% | N/A |
#5 | $0.4M | 6 | -68% | N/A |